At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
In Brief
A Phase 1 clinical trial evaluating BMS-936558 (MDX-1106) for Metastatic Castration-resistant Prostrate Cancer and 3 related conditions. Completed, enrolled 395 participants across 13 sites.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.
Study Details
Timeline
Interventions
Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response